HK-listed gold stocks jump as US economic fears boost bullion prices
VALENCIA, Calif. - AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in therapeutic acute wound care with annual revenues of $29.41 million, has announced the U.S. commercial launch of its new product, Cohealyx. This collagen-based dermal matrix is designed to support wound healing by facilitating cellular migration and revascularization, which is essential for creating an ideal wound bed for closure.
Cohealyx is the latest addition to AVITA’s wound care portfolio, which includes the RECELL System, an FDA-approved treatment for thermal burns and full-thickness skin defects, and PermeaDerm, a temporary biosynthetic dressing. AVITA’s integrated approach to wound care, combining these products, aims to improve clinical outcomes and expand the company’s market presence. According to InvestingPro data, the company maintains a modest revenue growth of 2.98% with a gross profit margin of 15.97%, though its overall financial health score indicates challenges ahead.
The company’s CEO, Jim Corbett, highlighted the potential benefits of Cohealyx, stating that in pre-clinical studies, wounds treated with the product were graft-ready faster than those treated with leading competitors. This could lead to faster healing and shorter hospital stays, consistent with the advantages offered by their flagship RECELL System. For detailed financial analysis and growth projections, investors can access additional insights through InvestingPro.
AVITA Medical is currently enrolling participants in the Cohealyx I trial, a post-market study designed to evaluate clinical outcomes and recovery timelines when Cohealyx is used in managing full-thickness wounds. This trial underscores the company’s commitment to supporting its product offerings with robust clinical data to demonstrate their benefits and cost-effectiveness. With the next earnings report expected on May 12, 2025, and an EBITDA of -$39.31M, investors should closely monitor the company’s progress in commercializing its product portfolio.
Cohealyx’s launch represents AVITA Medical’s continued efforts to provide innovative solutions in the therapeutic acute wound care market. The company also maintains exclusive rights to market, sell, and distribute Cohealyx and PermeaDerm in the U.S., with the RECELL System being approved for various skin healing applications in international markets. For comprehensive financial analysis and real-time updates on AVITA Medical’s market performance, visit InvestingPro.
This announcement is based on a press release statement from AVITA Medical, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.